Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol
- Development stage
- Unknown
- Lead developer
- Estrigenix Therapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the class of C-ring/A,C-ring modified benzopyran scaffolds. It is structurally related to flavonoids and functions as an experimental selective estrogen receptor modulator (SERM). The compound has been studied for its ability to bind both estrogen receptor alpha (ESR1) and estrogen receptor beta (ESR2), acting as a modulator of these nuclear hormone receptors. Its primary mechanism involves interaction with the ligand-binding domain of the estrogen receptors. There are no approved clinical indications or marketed products containing this molecule; it remains an experimental research tool in structural biology and pharmacology[5][6][10].
- Other names
- (3AS,4R,9BR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-olDC8DC-8DC 8A/C-ring modified benzopyran scaffold 4a
02
Targets
ESR2 (ERβ)ESR1 (ERα)
Beyond the preview
Go deeper on (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol.